OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug

TipRanks10-17

OKYO Pharma Limited Sponsored ADR (OKYO) has released an update. OKYO Pharma Limited has commenced a Phase 2 clinical trial for its drug OK-101, targeting neuropathic corneal pain (NCP), a rare and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476142165?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6MInUe1T4fs5TaG11G3efw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/87b9ff78d08b9d461f46ab67f57ff730","is_english":true,"pubTime":"2024-10-17 19:27","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2476142165","market":"us","top_or_hot":-1,"title":"OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug","media":"TipRanks","content":"<div>\n<p>OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.\nOKYO Pharma Limited has commenced a Phase 2 clinical trial for its drug OK-101, targeting neuropathic corneal pain (NCP), a rare and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/okyo-pharma-begins-key-phase-112730608.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-17 19:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/okyo-pharma-begins-key-phase-112730608.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.\nOKYO Pharma Limited has commenced a Phase 2 clinical trial for its drug OK-101, targeting neuropathic corneal pain (NCP), a rare and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/okyo-pharma-begins-key-phase-112730608.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/okyo-pharma-begins-key-phase-112730608.html","article_id":"2476142165","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6MInUe1T4fs5TaG11G3efw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/87b9ff78d08b9d461f46ab67f57ff730"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/okyo-pharma-begins-key-phase-112730608.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2476142165","pubTimestamp":1729164450,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"OKYO Pharma Limited Sponsored ADR  has released an update.OKYO Pharma Limited has commenced a Phase 2 clinical trial for its drug OK-101, targeting neuropathic corneal pain , a rare and debilitating eye condition lacking FDA-approved treatments. The trial aims to enroll 48 participants and follows promising results from a previous trial where OK-101 showed significant improvements in ocular pain associated with dry eye disease. This development marks a crucial step for OKYO as it continues to advance its innovative therapies for eye conditions in the pharmaceutical market.For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OKYO":"OKYO Pharma Limited"},"translate_title":"OKYO Pharma开始眼痛药物关键2期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OKYO":1},"content_text":"OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.\nOKYO Pharma Limited has commenced a Phase 2 clinical trial for its drug OK-101, targeting neuropathic corneal pain (NCP), a rare and debilitating eye condition lacking FDA-approved treatments. The trial aims to enroll 48 participants and follows promising results from a previous trial where OK-101 showed significant improvements in ocular pain associated with dry eye disease. This development marks a crucial step for OKYO as it continues to advance its innovative therapies for eye conditions in the pharmaceutical market.\nFor further insights into OKYO stock, check out TipRanks’ Stock Analysis page.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476142165"}